欢迎访问《现代生物医学进展》编辑部！

目的：对直肠癌患者进行联合贝伐单抗新辅助化疗的临床病理进行评估，研究贝伐单抗对肿瘤组织微血管的影响。方法：回顾性分析在我院普外科治疗的47 例直肠癌患者进行联合或不联合贝伐单抗（Bev）的新辅助化疗（NAC）治疗，用最大肿瘤直径评估肿瘤客观反应，用肿瘤消退分级评估肿瘤病理反应。结果：有31 例（66%）患者进行联合贝伐单抗（Bev）的新辅助化疗治疗（联合 Bev组）和其他16 例患者进行不联合Bev的新辅助化疗治疗（不联合Bev 组）。联合Bev组的肿瘤客观反应率明显高于不联合 Bev组（64.5 vs. 25.0 %，P=0.015）。联合Bev组(41.9 %)的病理反应率高于不联合Bev 组（41.9%vs. 12.5 %，p=0.052），但并没有明显差异。联合Bev 组的微血管密度（MVD）低于不联合Bev 组。结论：联合Bev的新辅助化疗治疗患者的靶向和病理反应好于不联合Bev 新辅助化疗的患者。联合Bev治疗患者的肿瘤组织的(MVD)受到抑制。

英文摘要:

Objective:To assess the clinicopathological benefit of bevacizumab (Bev.) in neoadjuvant chemotherapy (NAC) for rectal cancer patients and to investigate its influence on microvessel status in cancerous tissue.Methods:We retrospectively analyzed the data of 47 rectal cancer patients who received NAC with or without Bev. The objective response was evaluated using the maximum tumor diameter. Tumor regression grade was classified as a pathological response.Results:Thirty-one patients (66%) received NAC including Bev, as the Bev group; and the other 16 patients were treated without Bev, as the non-Bev group. The objective response rate was significantly higher in the Bev group than in the non-Bev group (64.5%vs.25.0%, p=0.015). The rate of pathological response was higher in the Bev group (41.9%) than in the non-Bev group (12.5 %, P=0.052), but difference was not statistically significant. The microvessel density (MVD) of the resected cancerous tissue was significantly lower in the Bev group than in the non-Bev group.Conclusion:The objective and pathological responses were better in patients treated with NAC plus Bev than in those who received NAC without Bev. Additionally, MVD in tumor tissues was inhibited in the patients treated with NAC plus Bev.

View Full Text View/Add Comment Download reader